Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection
Arnaud John Kombe Kombe, Ayesha Zahid, Ahmed Mohammed, et al.
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 19

Showing 19 citing articles:

Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
Hylemariam Mihiretie Mengist, Arnaud John Kombe Kombe, Daniel Mekonnen, et al.
Seminars in Immunology (2021) Vol. 55, pp. 101533-101533
Open Access | Times Cited: 107
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 32
Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies
Qingrui Huang, Xiaonan Han, Jinghua Yan
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 2412-2422
Open Access | Times Cited: 31
Key mutations in the spike protein of SARS‐CoV‐2 affecting neutralization resistance and viral internalization
Qiong Wang, Sheng‐Bao Ye, Zhijian Zhou, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 30
Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection
Titus Abiola Olukitibi, Zhujun Ao, Bryce M. Warner, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 545-545
Open Access | Times Cited: 23
A Randomized Trial of Sitagliptin and Spironolactone With Combination Therapy in Hospitalized Adults With COVID-19
Farhad Abbasi, Reuben Adatorwovor, Mohammad Ali Davarpanah, et al.
Journal of the Endocrine Society (2022) Vol. 6, Iss. 4
Open Access | Times Cited: 23
Immunoglobulin A response to SARS-CoV-2 infection and immunity
Khaleqsefat Esmat, Baban Jamil, Ramiar Kamal Kheder, et al.
Heliyon (2024) Vol. 10, Iss. 1, pp. e24031-e24031
Open Access | Times Cited: 6
SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice
María F. Pavan, Marina Bok, Rafael Betanzos San Juan, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 185-185
Open Access | Times Cited: 5
CD8+ T-cell immune escape by SARS-CoV-2 variants of concern
Arnaud John Kombe Kombe, Fleury Augustin Nsole Biteghe, Zélia Nelly Ndoutoume, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 21
Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
Mingtao Liu, Hui Gan, Zhiman Liang, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 13
The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19
Aline Almeida-Oliveira, Diana Freire, A. Andrade, et al.
Journal of Pharmaceutical Innovation (2023) Vol. 18, Iss. 3, pp. 1194-1212
Open Access | Times Cited: 12
Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-Cov-2 Infection
Titus Abiola Olukitibi, Zhujun Ao, Bryce M. Warner, et al.
(2023)
Open Access | Times Cited: 8
Effect of Double Mutation (L452R and E484Q) on the Binding Affinity of Monoclonal Antibodies (mAbs) against the RBD—A Target for Vaccine Development
Deepali Gupta, Mukesh Kumar, Priyanka Sharma, et al.
Vaccines (2022) Vol. 11, Iss. 1, pp. 23-23
Open Access | Times Cited: 9
SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges
Mingtao Liu, Zhiman Liang, Zhangkai J. Cheng, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 5
Closed Access | Times Cited: 4
Novel neutralizing chicken IgY antibodies targeting 17 potent conserved peptides identified by SARS-CoV-2 proteome microarray, and future prospects
Jin Li, Te Liang, Ailian Hei, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 6
Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants
María F. Pavan, Marina Bok, Rafael Betanzos San Juan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Development of a rapid image-based high-content imaging screening assay to evaluate therapeutic antibodies against the monkeypox virus
Krishna P. Kota, N.E. Ziolkowska, Jiayi Wei, et al.
Antiviral Research (2022) Vol. 210, pp. 105513-105513
Open Access | Times Cited: 5
Precision Vaccine Development: Unraveling the Immunoinformatics Code Against Epstein-Barr Virus's T41 Glycoprotein 350/220
Saba Beigh
Natural Resources for Human Health (2024) Vol. 4, Iss. 2, pp. 194-207
Open Access
Editorial: Host-microbe interaction in SARS-CoV-2 infection: mechanism and intervention
Arnaud John Kombe Kombe, Tengchuan Jin
Frontiers in Immunology (2023) Vol. 14
Open Access
Page 1

Scroll to top